Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Anna Couturier"'
Autor:
Julie R. Perlin, William J. Anderson, Sina Bartfeld, Anna Couturier, Yvanka de Soysa, R. Scott Hawley, Ping Hu, Yuin-Han Loh, Lolitika Mandal, Zubin Master, Alysson R. Muotri, Eugenia Piddini, Jose M. Polo, Esteban O. Mazzoni
Publikováno v:
Stem cell reports, vol 18, iss 2
The rapidly evolving stem cell field puts much stress on developing educational resources. The ISSCR Education Committee has created a flexible stem cell syllabus rooted in core concepts to facilitate stem cell literacy. The free syllabus will be upd
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::057cac52cdda03625f79a26fa6844747
https://escholarship.org/uc/item/6488f3b0
https://escholarship.org/uc/item/6488f3b0
Publikováno v:
Mcwhirter, L, Smyth, H, Hoeritzauer, I, Couturier, A, Stone, J & Carson, A J 2022, ' What is brain fog? ', Journal of Neurology, Neurosurgery & Psychiatry, pp. jnnp-2022-329683 . https://doi.org/10.1136/jnnp-2022-329683
BackgroundThe term ‘brain fog’ is increasingly used colloquially to describe difficulties in the cognitive realm. But what is brain fog? What sort of experiences do people talk about when they talk about brain fog? And, in turn, what might this t
Publikováno v:
Regenerative Medicine. 14:1137-1150
Aim: This study examines online enquiries received by two prominent stem cell science initiatives operating in different geographical jurisdictions. Materials & methods: Combined quantitative and qualitative analysis undertaken of internet-based quer
Publikováno v:
Journal of Neurology, Neurosurgery & Psychiatry. 93:e3.18
ObjectivesThe term ‘brain fog’ is increasingly used in social and other media. But what is brain fog? What sort of experiences do people talk about when they talk about brain fog? And, in turn, what might this tell us about potential underlying p
Publikováno v:
SSCI
On October 1st, 2019 in response to critique from patient advocates and the medical community, Google explicitly prohibited promotion of unproven stem cell and gene therapy treatments on their platform in order to protect users from rising direct-to-
Bortezomib-dexamethasone is widely used for relapsed myeloma in routine clinical practice, but comparative data versus single-agent bortezomib are lacking. This retrospective analysis compared second-line treatment with bortezomib-dexamethasone and b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::1fda2443cc6dfc768a743ff324af5bbd
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:2953943
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:2953943